U.S. markets open in 3 hours 19 minutes
  • S&P Futures

    3,795.25
    -21.50 (-0.56%)
     
  • Dow Futures

    31,120.00
    -116.00 (-0.37%)
     
  • Nasdaq Futures

    12,583.00
    -98.75 (-0.78%)
     
  • Russell 2000 Futures

    2,187.30
    -18.50 (-0.84%)
     
  • Crude Oil

    60.95
    -0.33 (-0.54%)
     
  • Gold

    1,713.20
    -2.60 (-0.15%)
     
  • Silver

    25.97
    -0.42 (-1.58%)
     
  • EUR/USD

    1.2047
    -0.0020 (-0.17%)
     
  • 10-Yr Bond

    1.4700
    0.0000 (0.00%)
     
  • Vix

    27.43
    +3.33 (+13.82%)
     
  • GBP/USD

    1.3929
    -0.0024 (-0.17%)
     
  • USD/JPY

    107.3400
    +0.3380 (+0.32%)
     
  • BTC-USD

    49,334.42
    -2,144.79 (-4.17%)
     
  • CMC Crypto 200

    989.40
    +2.19 (+0.22%)
     
  • FTSE 100

    6,604.15
    -71.32 (-1.07%)
     
  • Nikkei 225

    28,930.11
    -628.99 (-2.13%)
     

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Merger of Tetraphase Pharmaceuticals, Inc. with AcelRx Pharmaceuticals, Inc. is Fair to TTPH Shareholders

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / March 17, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:

To: All Persons or Entities who purchased Tetraphase Pharmaceuticals, Inc. ("Tetraphase" or the "Company") (TTPH) stock prior to March 16, 2020.

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the merger of Tetraphase with AcelRx Pharmaceuticals, Inc. ("AcelRx") (ACRX). Under the terms of the agreement, Tetraphase stockholders will receive, for each share of Tetraphase common stock, 0.6303 of a share of AcelRx common stock and one contingent value right. To learn more about the action and your rights, go to https://www.zlk.com/mna2/tetraphase-pharmaceuticals-inc-loss-form or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

The Tetraphase merger investigation concerns whether the Board of Tetraphase breached their fiduciary duties to stockholders by agreeing to enter into this transaction and whether the merger undervalues Tetraphase relative to AcelRx, thereby harming Tetraphase shareholders.

Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky LLP



View source version on accesswire.com:
https://www.accesswire.com/581235/SHAREHOLDER-ALERT-Levi-Korsinsky-LLP-Notifies-Investors-of-an-Investigation-Regarding-Whether-the-Merger-of-Tetraphase-Pharmaceuticals-Inc-with-AcelRx-Pharmaceuticals-Inc-is-Fair-to-TTPH-Shareholders